NFL Biosciences SAS (ALNFL) - Total Assets
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) holds total assets worth €4.42 Million EUR (≈ $5.17 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NFL Biosciences SAS investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NFL Biosciences SAS - Total Assets Trend (2018–2024)
This chart illustrates how NFL Biosciences SAS's total assets have evolved over time, based on quarterly financial data. Check NFL Biosciences SAS (ALNFL) tangible equity ratio to evaluate the tangible quality of the company's equity base.
NFL Biosciences SAS - Asset Composition Analysis
Current Asset Composition (December 2024)
NFL Biosciences SAS's total assets of €4.42 Million consist of 92.5% current assets and 7.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 53.0% |
| Accounts Receivable | €1.06 Million | 29.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €145.28K | 4.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how NFL Biosciences SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALNFL market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NFL Biosciences SAS's current assets represent 92.5% of total assets in 2024, an increase from 41.9% in 2018.
- Cash Position: Cash and equivalents constituted 53.0% of total assets in 2024, up from 26.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 29.3% of total assets.
NFL Biosciences SAS Competitors by Total Assets
Key competitors of NFL Biosciences SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs20.23 Billion |
|
Pharming Group NV
AS:PHARM
|
Netherlands | €473.79 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
Germany | €145.77 Million |
NFL Biosciences SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.13 | 3.17 | 0.37 |
| Quick Ratio | 4.13 | 3.17 | 0.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.14 Million | €3.23 Million | €-732.16K |
NFL Biosciences SAS - Advanced Valuation Insights
This section examines the relationship between NFL Biosciences SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.81 |
| Latest Market Cap to Assets Ratio | 3.37 |
| Asset Growth Rate (YoY) | -9.1% |
| Total Assets | €3.61 Million |
| Market Capitalization | $12.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NFL Biosciences SAS's assets at a significant premium (3.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NFL Biosciences SAS's assets decreased by 9.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NFL Biosciences SAS (2018–2024)
The table below shows the annual total assets of NFL Biosciences SAS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.61 Million ≈ $4.22 Million |
-9.09% |
| 2023-12-31 | €3.97 Million ≈ $4.64 Million |
+65.75% |
| 2022-12-31 | €2.40 Million ≈ $2.80 Million |
-35.00% |
| 2021-12-31 | €3.69 Million ≈ $4.31 Million |
+539.09% |
| 2020-12-31 | €576.64K ≈ $674.15K |
+23.48% |
| 2019-12-31 | €466.99K ≈ $545.96K |
+75.64% |
| 2018-12-31 | €265.88K ≈ $310.84K |
-- |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more